Have we forgotten all about NAFLD?  There was no mention of it yesterday.

Also: eGFR between 20 and 60...from what I've read about Forxiga (Farxiga - Dapagliflozin/SGLT2i AstraZeneca) its recommended for patients with an eGFR of 45 and above.  Forxiga is contraindicated for patients with an eGFR below 30...so, their "system can't tolerate it"?? (I'm not sure)

So, maybe the same thing for Empagliflozin and Canagliflozin?? 

If we take on the sickest of the sick it seems to me we're going beyond the current limits of some of the most common SGLT2 inhibitors.  If we include patients with an eGFR of 20 - 30 what are they on if they can no longer be on SGLT2i?...metformin?

...And lets not forget, Dapagliflozin (Forxiga) is now approved in Europe and the USA for patients with AND WITHOUT T2D (for HF).  I think RVX 208 eventually ends up with approval for patients without T2D as well, but that would be a looooong way off. 

https://twitter.com/GideonHealth/status/1244546213095112704